Literature DB >> 23402464

The evolution of oral anticoagulant therapy.

Christopher Dittus1, Jack Ansell.   

Abstract

Before the advent of oral, targeted anticoagulants, physicians had no choice regarding the type of oral anticoagulant prescribed, as every patient received warfarin. The new oral direct thrombin and factor Xa inhibitors give the prescribing physician, as well as the patient, greater choice. Variation in dosing, half-life, elimination, monitoring, and reversal will help the clinician decide on the appropriate anticoagulant for the appropriate patient. Rather than replace warfarin, each anticoagulant will now have a particular niche, and the decision of which agent to prescribe will be determined at the bedside.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23402464     DOI: 10.1016/j.pop.2012.11.011

Source DB:  PubMed          Journal:  Prim Care        ISSN: 0095-4543            Impact factor:   2.907


  4 in total

1.  Thrombosis on a mechanical mitral valve anticoagulated with dabigatran.

Authors:  Stephanie Coulter; Karla Campos
Journal:  J Thromb Thrombolysis       Date:  2014       Impact factor: 2.300

2.  Patient perspectives of dabigatran: analysis of online discussion forums.

Authors:  Mary S Vaughan Sarrazin; Peter Cram; Alexandur Mazur; Melissa Ward; Heather Schacht Reisinger
Journal:  Patient       Date:  2014       Impact factor: 3.883

Review 3.  A new paradigm shift in antithrombotic therapy.

Authors:  Anita Pudusseri; Raji Shameem; Alex C Spyropoulos
Journal:  Front Pharmacol       Date:  2013-10-21       Impact factor: 5.810

4.  Trends in antithrombotic drug use and adherence to non-vitamin K oral anticoagulants in the Netherlands.

Authors:  Susan Hanemaaijer; Fong Sodihardjo; Annemieke Horikx; Michel Wensing; Peter A G M De Smet; Marcel L Bouvy; Martina Teichert
Journal:  Int J Clin Pharm       Date:  2015-08-05
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.